接受间充质干细胞治疗的卒中患者循环细胞外囊泡:一项随机试验的生物标志物分析
STARTING-2 试验的事后生物标志物分析纳入慢性重症卒中患者,按 2:1 随机接受自体间充质干细胞静脉注射(39 例)或标准治疗(15 例),随访 3 个月。注射后 24 小时内循环细胞外囊泡水平升高约 5 倍(P=0.001),校正混杂因素后仅囊泡数量与运动功能改善独立相关(OR 5.718)。
要点
- 自体间充质干细胞静脉注射后 24 小时内循环细胞外囊泡升高约 5 倍。
- 校正年龄、性别、基线卒中严重度和发病至治疗时间后,仅细胞外囊泡数量与运动功能改善独立相关(OR 5.718)。
- 与神经发生/神经可塑性相关的微 RNA(如 microRNA-18a-5p)在治疗后循环细胞外囊泡中显著升高(P=0.0479),营养因子水平未变。
核心结论
- 该试验首次显示,对缺血性卒中患者进行间充质干细胞治疗可显著增加循环细胞外囊泡,且其与运动功能改善及磁共振成像可塑性指标显著相关。
研究设计与样本
- 前瞻性随机对照试验,慢性重症卒中患者按 2:1 比例分配接受自体间充质干细胞静脉注射(干细胞组 n=39)或标准治疗(对照组 n=15),随访 3 个月。
- 评估详细临床评定及弥散张量成像和静息态功能磁共振成像的神经可塑性,并在干细胞治疗前后采集系列样本。
主要发现
- 注射间充质干细胞后 24 小时内循环细胞外囊泡水平升高约 5 倍(均值±标准差,从 2.7×10^9±2.2×10^9 至 1.3×10^10±1.7×10^10 个/mL,P=0.001)。
- 校正年龄、性别、基线卒中严重度和卒中发病至治疗时间间隔后,仅细胞外囊泡数量与运动功能改善独立相关(OR 5.718,针对细胞外囊泡数量对数,95%CI 1.144-28.589,P=0.034)。
- 弥散张量成像和静息态功能磁共振成像显示,同侧皮质脊髓束完整性和同侧半球内运动网络分别与循环细胞外囊泡水平显著相关(P<0.05)。
- 与神经发生/神经可塑性相关的微 RNA(如 microRNA-18a-5p)在间充质干细胞治疗后循环细胞外囊泡中显著升高(P=0.0479)。
- 相比之下,间充质干细胞治疗后营养因子水平未发生变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mesenchymal stem cells (MSCs) secrete trophic factors and extracellular vesicles (EVs). However, the level and role of EVs after MSC therapy in patients with stroke are unknown. We investigated whether circulating EVs and trophic factors are increased after MSCs and are related to the therapeutic benefits in the STARTING-2 trial (Stem Cell Application Researches and Trials in Neurology-2) participants. METHODS: In this prospective randomized controlled trial, patients with chronic major stroke were assigned, in a 2:1 ratio, to receive autologous MSC intravenous injection (MSC group, n=39) or standard treatment (control group, n=15) and followed for 3 months. Detailed clinical assessment and neuroplasticity on diffusion tensor image and resting-state functional magnetic resonance imaging were evaluated. Serial samples were collected, before/after MSCs therapy. The primary outcome measure was circulating factors that are associated with the clinical improvement in the Fugl-Meyer Assessment (secondary end point of the trial) and neuroplasticity on diffusion tensor image and resting-state functional magnetic resonance imaging. Additional outcome measures were microRNAs and trophic factors enriched in the plasma EVs, obtained using quantitative polymerase chain reaction and ELISA, respectively. RESULTS: Circulating EV levels were increased ≈5-fold (mean±SD, from 2.7×109±2.2×109 to 1.3×1010±1.7×1010 EVs/mL) within 24 hours after injection of MSCs (P=0.001). After adjustment of age, sex, baseline stroke severity, and the time interval from stroke onset to treatment, only the EV number was independently associated with improvement in motor function (odds ratio, 5.718 for EV numberLog [95% CI, 1.144-28.589]; P=0.034). Diffusion tensor image and resting-state functional magnetic resonance imaging showed that integrity of the ipsilesional corticospinal tract and intrahemispheric motor network were significantly correlated with circulating EV levels, respectively (P<0.05). MicroRNAs related to neurogenesis/neuroplasticity (eg, microRNA-18a-5p) were significantly increased in circulating EVs after MSC therapy (P=0.0479). In contrast, trophic factor levels were not changed after MSC therapy. CONCLUSIONS: This trial is the first to show that treatment of ischemic stroke patients with MSCs significantly increases circulating EVs, which were significantly correlated with improvement in motor function and magnetic resonance imaging indices of plasticity. REGISTRATION: URL: https://www. CLINICAL TRIALS: gov; Unique identifier: NCT01716481.
引用
- Bang OY, Kim EH, Cho YH, et al. Circulating Extracellular Vesicles in Stroke Patients Treated With Mesenchymal Stem Cells: A Biomarker Analysis of a Randomized Trial. Stroke. 2022. PMID: 35341320. doi:10.1161/STROKEAHA.121.036545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。